A synergistic therapeutic nano-eyedrop for dry eye disease based on ascorbic acid-coupled exosomes

Dry eye disease (DED), a complex ocular surface disease with a high prevalence rate, is associated with corneal injury, excess oxidative stress and inflammation. Current therapeutic strategies, including artificial tears and anti-inflammatory agents, are unable to address all the deleterious factors...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale 2023-01, Vol.15 (4), p.189-1899
Main Authors: Ma, Fang, Feng, Jing, Liu, Xi, Tian, Ying, Wang, Wen-Jing, Luan, Fu-Xiao, Wang, Ying-Jie, Yang, Wei-Qiang, Bai, Jing-Yi, Zhang, Yi-Quan, Tao, Yong
Format: Article
Language:English
Subjects:
Animals
Anti-Inflammatory Agents
Ascorbic acid
Ascorbic Acid - pharmacology
Chemical compounds
Dry Eye Syndromes - drug therapy
Exosomes - metabolism
Eye diseases
Gold
Gold - pharmacology
Metal Nanoparticles - therapeutic use
Mice
Nanoparticles
Ophthalmic Solutions
Pharmacology
Phospholipids
Side effects
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dry eye disease (DED), a complex ocular surface disease with a high prevalence rate, is associated with corneal injury, excess oxidative stress and inflammation. Current therapeutic strategies, including artificial tears and anti-inflammatory agents, are unable to address all the deleterious factors or to achieve a clinical cure due to their temporary or side effects. Here, we prepared a multiple-functional eyedrop based on the deposition of gold nanoparticles (AuNPs) reduced by ascorbic acid (AA) onto the exosomal phospholipid membrane of mesenchymal stem cell (mExo)-derived exosomes in situ (mExo@AA). The therapeutic value of mExo@AA for DED was demonstrated in a mouse DED model. Combining the benefits of mExo and AA, mExo@AA effectively improves corneal epithelium recovery and anti-inflammation capacity, decreases corneal reactive oxygen species, and restores tear secretion without adverse effects. Thus, this study suggests that mExo@AA is effective and safe as a therapeutic agent for the treatment of DED. The advanced eyedrop, mExo@AA was synthesized by reducing gold nanoparticles onto the exosomal phospholipid membrane in situ using AA. In the BAC-induced mice model, mExo@AA demonstrated superior damage repair, ROS scavenging, and anti-inflammation.
ISSN:2040-3364
2040-3372
DOI:10.1039/d2nr05178h